PhRMA Statement on 340B ACCESS Act

Sample article from our Government & Public Policy

May 28, 2024 (press release) –

WASHINGTON, D.C. (May 28, 2024) – Today, Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl released the following statement:

“Over the decades, the 340B program has lost its way and become a piggy bank for many, with large hospitals, PBMs and pharmacy chains siphoning money from the program without using it to improve access to lower cost medicines in their communities. The 340B ACCESS Act would put an end to that, marking a major milestone in the longstanding effort to fix the 340B program so that it works better for patients and true safety-net providers.

“When we joined forces with the National Association of Community Health Centers over a year ago, our hope was that it would lead to Congress pursuing a comprehensive set of changes to the program – including patient affordability requirements, clarifications around hospital eligibility and enforceable accountability measures. Today, we’re seeing that become a reality, showing the value of stakeholders coming together to solve our nation’s health care problems.”

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order government & public policy coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy. We won't track your information when you visit our site. But in order to comply with your preferences, we'll have to use just one tiny cookie so that you're not asked to make this choice again.